Pharmaceuticals, Biotechnology & Life Sciences

Pfizer’s 2026 earnings reveal a 226% payout and a 36.7× trailing P/E, yet the company is poised to thrive amid a looming biosimilar boom and patent expiries.

FDA accepts Anaphylm™ sublingual epinephrine NDA resubmission, setting a March 2027 review date and opening a first‑in‑class oral allergy rescue market.

Formycon’s FDA review of FYB206, the first Keytruda biosimilar, sparked a 15% share jump and positions the company for a multi‑billion‑euro oncology breakthrough.

Nicox S.A.: A biotech eye‑care innovator battling declining stock and negative earnings while seeking growth through high‑profile partnerships.

Rezolute’s focus on innovative metabolic and orphan drug therapies shows promise despite volatile stock and a negative P/E, positioning it for long‑term growth in global healthcare.

Regeneron confirms Pasatru’s 56‑week extension shows zero new HO lesions and reduced flare‑ups, while a new GLP‑1 study preserves lean mass during weight loss.

Explore Personalis Inc.’s genomic breakthroughs and latest stock trends: $15.85 share price, stable market presence, and innovative cancer therapy insights.

Geron unveils new telomerase‑inhibitor data for myeloid malignancies, showing prolonged transfusion independence and predictive early blood‑cell declines.

Discover how Avant Brands Inc. is reshaping Canada’s cannabis market with handcrafted products and bold growth plans—analyzing stock volatility, market strategy, and future prospects.

ADMA Biologics drives plasma‑derived therapeutic innovation, boosting production capacity, supply resilience, and investor value in a growing biotech sector.